Drugs / Andes virus DNA vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03682107 | Feb 2019 → Sep 2020 | hantavirus pulmonary syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Andes virus DNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03682107 ↗ |
| Known as | ANDV DNA vaccine | “Subjects assigned to the 3 dose regimen will receive ANDV DNA vaccine on Days 1, 29 and 169, and placebo on Day 57.” NCT03682107 ↗ |
| Modality | Vaccine | “A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV)” NCT03682107 ↗ |